Research
William Blair Initiates Rapport Therapeutics at Outperform
Rapport Therapeutics (RAPP) has an average rating of buy and mean price target of $60.28, according to analysts polled by FactSet.
$RAPP
$RAPP
3 stories mentioning RAPPUpdated 56d ago
Every FINWIRES story that references RAPP, newest first.
What are analysts saying about RAPP?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on RAPP?
Research
Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target
Rapport Therapeutics (RAPP) has an average rating of buy and mean price target of $58.30, according to analysts polled by FactSet.
$RAPP
Insider Trading
Rapport Therapeutics Insider Sold Shares Worth $695,823, According to a Recent SEC Filing
Krishnaswamy Yeleswaram, Chief Development Officer, on April 10, 2026, sold 19,865 shares in Rapport Therapeutics (RAPP) for $695,823. Following the Form 4 filing with the SEC, Yeleswaram has control over a total of 266,651 common shares of the company, with 266,651 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2012593/000119312526154908/xslF345X05/ownership.xml
$RAPP
